A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients

Exclusion Criteria

• •Pregnant and breastfeeding women
• •Subjects requiring a planned PCI procedure after 1 month of index procedure
• •Active bleeding at the time of inclusion
• •Cardiogenic shock
• •A known hypersensitivity or contraindication to aspirin, heparin and bivalirudin, P2Y12 inhibitors, mTOR inhibiting drugs such as zotarolimus, Biolimus A9 (or its derivatives), cobalt, nickel, platinum, iridium, chromium, molybdenum, polymer coatings (eg, BioLinx™), stainless steel (or other metal ions found in 316L stainless steel), zinc, or a sensitivity to contrast media, which cannot be adequately pre-medicated.
• •PCI during the previous 6 months for a lesion other than the target lesion of the index procedure
• •Participation in another clinical study within 12 months after index procedure
• •Subjects with life expectancy of less than 2 years